Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Bone Marrow Transplant
    October 2026
  1. PAVIGLIANITI A, Fekom M, Halahleh K, Benakli M, et al
    BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT.
    Bone Marrow Transplant. 2026 Oct 6. doi: 10.1038/s41409-026-03043.
    >> Share

    September 2026
  2. ARVANITIS I, Maschio C, Panaretos D, Osorio Zuluaga J, et al
    Reduced-intensity T-replete allogeneic stem cell transplantation provides long-term survival in relapsed angioimmunoblastic T-cell lymphoma post-autologous transplant in patients over the age of 50.
    Bone Marrow Transplant. 2026 Sep 23. doi: 10.1038/s41409-026-03037.
    >> Share

  3. SCHROEDER JC, Peczynski C, Berning P, Michel E, et al
    Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.
    Bone Marrow Transplant. 2026 Sep 1. doi: 10.1038/s41409-026-02979.
    >> Share

    August 2026
  4. MANSON G, Di Blasi R, Houot R, Morschhauser F, et al
    Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
    Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03001.
    >> Share

  5. WALKER I, Deotare U, Elemary M, Elsawy M, et al
    A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study
    Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03024.
    >> Share

  6. LIU J, Wang C, Min H, Chen J, et al
    A real-world, multi-center, retrospective study of autologous hematopoietic stem cell transplantation in 33 patients with HIV-associated lymphoma in China (CALL-006 Study).
    Bone Marrow Transplant. 2026 Aug 19. doi: 10.1038/s41409-026-02973.
    >> Share

  7. IACOBONI G, Barba P, Khvedelidze I, Ngoya M, et al
    Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.
    Bone Marrow Transplant. 2026 Aug 18. doi: 10.1038/s41409-026-03013.
    >> Share

    July 2026
  8. SHEN YG, Chen SY, Mu RJ, Li HY, et al
    Chidamide?augmented BEAM conditioning and maintenance in first-remission T?cell lymphoma: a single?arm phase 2 experience.
    Bone Marrow Transplant. 2026 Jul 18. doi: 10.1038/s41409-026-02992.
    >> Share

  9. SAHA A, Whiting J, Mohty R, Flores K, et al
    A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.
    Bone Marrow Transplant. 2026 Jul 17. doi: 10.1038/s41409-026-02936.
    >> Share

  10. DREGER P, Iacoboni G, Robinson S, Bazarbachi A, et al
    Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.
    Bone Marrow Transplant. 2026 Jul 9. doi: 10.1038/s41409-026-02963.
    >> Share

  11. TU J, Zou R, Ping N, Zhu Q, et al
    Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.
    Bone Marrow Transplant. 2026 Jul 6. doi: 10.1038/s41409-026-02967.
    >> Share

    June 2026
  12. RICARD L, Stocker N, Banet A, Brissot E, et al
    The role of allogeneic stem cell transplantation in peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2026 Jun 29. doi: 10.1038/s41409-026-02962.
    >> Share

  13. OSSAMI SAIDY A, Boumendil A, Dreger P, Stella F, et al
    The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).
    Bone Marrow Transplant. 2026 Jun 19. doi: 10.1038/s41409-026-02913.
    >> Share

  14. DACHY G, Mooyaart JE, Gabellier L, Yakoub-Agha I, et al
    Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.
    Bone Marrow Transplant. 2026 Jun 6. doi: 10.1038/s41409-026-02925.
    >> Share

    May 2026
  15. DADA R, Apostolidis J, Ibrahim RB, Salem AA, et al
    Role of consolidative radiotherapy in preventing relapses and subsequent salvage ASCT in early-stage classic Hodgkin lymphoma.
    Bone Marrow Transplant. 2026 May 28. doi: 10.1038/s41409-026-02921.
    >> Share

    April 2026
  16. LI J, Feng S, Jia S, Zhang Y, et al
    Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma.
    Bone Marrow Transplant. 2026 Apr 14. doi: 10.1038/s41409-026-02858.
    >> Share

    March 2026
  17. FACCHIN G, Battista ML, Olivieri J, Pasquale R, et al
    Bispecific antibodies followed by allogeneic hematopoietic stem cell transplantation as rescue therapy in refractory/relapsed B cell non-Hodgkin lymphoma: a real-life experience.
    Bone Marrow Transplant. 2026 Mar 9. doi: 10.1038/s41409-026-02812.
    >> Share

  18. CANELO-VILASECA M, Sabbah M, Cristinelli C, Bommier C, et al
    Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
    Bone Marrow Transplant. 2026 Mar 2. doi: 10.1038/s41409-026-02809.
    >> Share

    February 2026
  19. YAGI Y, Kanemasa Y, Goto H, Yamamoto M, et al
    Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.
    Bone Marrow Transplant. 2026 Feb 14. doi: 10.1038/s41409-026-02802.
    >> Share

    January 2026
  20. KRAMER I, Konig L, Brecht A, Hassel JC, et al
    Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma.
    Bone Marrow Transplant. 2026 Jan 20. doi: 10.1038/s41409-025-02796.
    >> Share

  21. SIMON L, Vucinic V, Rejeski K, Schubert ML, et al
    Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.
    Bone Marrow Transplant. 2026 Jan 16. doi: 10.1038/s41409-025-02789.
    >> Share

  22. CANELO-VILASECA M, Sabbah M, Cristinelli C, Come B, et al
    Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
    Bone Marrow Transplant. 2026 Jan 8. doi: 10.1038/s41409-025-02754.
    >> Share

  23. LOPEZ-PEREIRA P, Bazarbachi A, Marcais A, Ngoya M, et al
    Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.
    Bone Marrow Transplant. 2026 Jan 3. doi: 10.1038/s41409-025-02783.
    >> Share

    December 2025
  24. PUCKRIN R, Sapon-Cousineau V, Peters A, Owen C, et al
    Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
    Bone Marrow Transplant. 2025 Dec 26. doi: 10.1038/s41409-025-02786.
    >> Share

  25. CHANG YS, Hsieh WC, Chang HM, Ko BS, et al
    Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Dec 18. doi: 10.1038/s41409-025-02773.
    >> Share

  26. EASTON N, Goldfarb DG, El-Naas A, Kam R, et al
    Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis.
    Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02758.
    >> Share

  27. DAMAJ G, de Masson A, Dreger P, Bazarbachi A, et al
    Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
    Bone Marrow Transplant. 2025;60:1565-1573.
    >> Share

    November 2025
  28. LOPEZ-PEREIRA P, Romero Dominguez S, Martin-Moro F, Caballero AC, et al
    Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis.
    Bone Marrow Transplant. 2025 Nov 27. doi: 10.1038/s41409-025-02772.
    >> Share

  29. CORONA M, Brown S, Rejeski K, Flynn JR, et al
    Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.
    Bone Marrow Transplant. 2025 Nov 18. doi: 10.1038/s41409-025-02745.
    >> Share

  30. LINDAUER M, Reissfelder F, Hegenbart U, Luft T, et al
    Long-term disease control of monomorphic epitheliotrophic intestinal T-cell lymphoma (MEITL) with CNS involvement in a caucasian patient by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02747.
    >> Share

  31. KURIYAMA K, Watanabe M, Okatani T, Ota S, et al
    Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02752.
    >> Share

    September 2025
  32. TORRENT A, Morgades M, Iacoboni G, Reguera JL, et al
    Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.
    Bone Marrow Transplant. 2025 Sep 30. doi: 10.1038/s41409-025-02722.
    >> Share

    August 2025
  33. DONG Y, Yang T, Zhao M, Song F, et al
    Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
    >> Share

    June 2025
  34. BEKADJA MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, et al
    Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664.
    >> Share

  35. DHOLARIA B, Bhaskar ST, Patel VG, Biltibo E, et al
    Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial.
    Bone Marrow Transplant. 2025;60:769-772.
    >> Share

    May 2025
  36. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
    Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
    >> Share

    April 2025
  37. ABRAMOVICH A, Adam E, Shapira A, Hutt D, et al
    CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615.
    >> Share

  38. MARTINEZ C, Khvedelidze I, Fekom M, Deau Fischer B, et al
    Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA,
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568.
    >> Share

  39. DREGER P, Ahmed S, Bazarbachi A, Dietrich S, et al
    How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
    Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599.
    >> Share

  40. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
    Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
    >> Share

  41. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    >> Share

    March 2025
  42. CANELO-VILASECA M, Sabbah M, Di Blasi R, Cristinelli C, et al
    Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
    Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539.
    >> Share

  43. KHARFAN-DABAJA MA, Mohty R, Easwar N, Johnston P, et al
    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
    Bone Marrow Transplant. 2025 Mar 1. doi: 10.1038/s41409-025-02541.
    >> Share

  44. LOSI G, Mussetti A, Pena M, Lopez-Pereira P, et al
    Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.
    Bone Marrow Transplant. 2025;60:259-269.
    >> Share

    February 2025
  45. KRAMER I, Konig L, Luft T, Hegenbart U, et al
    Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02522.
    >> Share

  46. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    >> Share

  47. CORONA M, Ip A, Brown S, Luna A, et al
    Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 1. doi: 10.1038/s41409-025-02519.
    >> Share

    December 2024
  48. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    >> Share

  49. RAMDIAL J, Lin R, Thall PF, Valdez BC, et al
    High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
    Bone Marrow Transplant. 2024;59:1754-1762.
    >> Share

    November 2024
  50. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    >> Share

  51. RICHARDSON T, Tharmaseelan H, Frenzel L, Godel P, et al
    Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02472.
    >> Share

  52. ZHANG X, Xu K, Gale RP, Pan B, et al
    Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02463.
    >> Share

    October 2024
  53. BRAMANTI S, Mannina D, Chiappella A, Casadei B, et al
    Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study.
    Bone Marrow Transplant. 2024 Oct 9. doi: 10.1038/s41409-024-02427.
    >> Share

  54. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    >> Share

    September 2024
  55. NISHIKUBO M, Shimomura Y, Nakaya Y, Shinohara A, et al
    Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02423.
    >> Share

    August 2024
  56. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    >> Share

  57. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    >> Share

    April 2024
  58. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
    >> Share

    March 2024
  59. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    >> Share

  60. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
    >> Share

    February 2024
  61. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    >> Share

  62. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
    A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
    >> Share

  63. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    >> Share

  64. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    >> Share

    January 2024
  65. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
    Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
    >> Share

  66. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    >> Share

  67. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    >> Share

  68. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    >> Share

  69. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    >> Share

    December 2023
  70. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    >> Share

  71. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    >> Share

  72. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    >> Share

  73. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    >> Share

    November 2023
  74. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    >> Share

  75. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    >> Share

    October 2023
  76. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    >> Share

  77. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    >> Share

    September 2023
  78. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    >> Share

  79. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016